Dr. Reddy’s Laboratories (RDY) Expected to Post Earnings on Wednesday

Dr. Reddy’s Laboratories (NYSE:RDY) will likely be posting its Q1 26/27 results before the market opens on Wednesday, July 22nd. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.0918 per share and revenue of $854.1960 million for the quarter. Parties may review the information on the company’s upcoming Q1 26/27 earning summary page for the latest details on the call scheduled for Wednesday, July 22, 2026 at 10:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $852.55 million for the quarter, compared to the consensus estimate of $886.58 million. Dr. Reddy’s Laboratories had a net margin of 12.90% and a return on equity of 12.34%. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Trading Up 0.3%

Shares of RDY stock opened at $12.63 on Monday. Dr. Reddy’s Laboratories has a fifty-two week low of $12.19 and a fifty-two week high of $15.67. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.34 and a current ratio of 1.80. The stock has a 50 day simple moving average of $13.61 and a two-hundred day simple moving average of $13.70. The company has a market cap of $10.55 billion, a P/E ratio of 21.78, a PEG ratio of 1.90 and a beta of 0.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in shares of Dr. Reddy’s Laboratories by 7.6% during the second quarter. Invesco Ltd. now owns 253,342 shares of the company’s stock valued at $3,808,000 after acquiring an additional 17,907 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after purchasing an additional 1,294 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Dr. Reddy’s Laboratories by 23.3% in the 2nd quarter. First Trust Advisors LP now owns 65,652 shares of the company’s stock worth $987,000 after purchasing an additional 12,390 shares in the last quarter. Sei Investments Co. grew its position in Dr. Reddy’s Laboratories by 37.3% in the 2nd quarter. Sei Investments Co. now owns 124,136 shares of the company’s stock valued at $1,866,000 after purchasing an additional 33,747 shares during the period. Finally, Quantinno Capital Management LP increased its stake in Dr. Reddy’s Laboratories by 92.6% during the 2nd quarter. Quantinno Capital Management LP now owns 235,044 shares of the company’s stock valued at $3,533,000 after purchasing an additional 112,988 shares in the last quarter. Institutional investors own 3.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RDY. The Goldman Sachs Group downgraded shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, April 23rd. Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dr. Reddy’s Laboratories currently has a consensus rating of “Reduce”.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.